Institut Regional du Cancer Montpellier ( Site 1106)

Montpellier, Herault 34298

0 studies enrolling now · 1 studies all time

What they study most

Neoplasm Malignant

Studies at this site

• Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) — Running, not enrolling